


**ABSTRACT OF THE DISCLOSURE**

The specification discloses compounds selected from those of formula (I):



or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, wherein

R<sub>2</sub>, m, A, Z<sub>1</sub>, n, G<sub>2</sub>, X<sub>1</sub>, X<sub>2</sub>, X<sub>3</sub>, G<sub>1</sub>, and R<sub>1</sub> are as defined in the specification, wherein the compound of formula (I) is not 6-(2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine)-benzoate, 6-phenylthio-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzylsulphonyl-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine, 6-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-benzothiazine or 6-(2,4-dihydroxy)-benzophenone-2,4-dioxo-3,4-dihydro-2H-1,3-

benzothiazine. The specification also discloses processes for preparing the compounds, pharmaceutical compositions comprising said compounds of formula (I) or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof, and methods of treating diseases or disorders mediated by a MMP-13 enzyme or responsive to treatment with an inhibitor of a MMP-13 enzyme, comprising administering said compounds of formula (I) or a racemic form, isomer, N-oxide, or pharmaceutically acceptable salt thereof.